drugset / Trial / NCT07048743

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer

NCT07048743 ↗

Phase 2 Recruiting 15 enrolled University Health Network, Toronto
NaSingle-groupOpen-labelSupportive care

Summary

The PEARL-C1 trial is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.

Timeline

Start
2025-07-16
Primary completion
2027-12-02
Completion
2027-12-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 25 mg Oral

Indications

No indication recorded.